BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 11/18/22

The presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as a platform for development of therapeutics addressing diseases with large unmet m...

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. The company’s CEO Amir Reichman, as an international subject ...

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today congratulated its co-lead scientific research collaborator ...

JERUSALEM, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”) , a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment ...

JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment o...

BiondVax has an exclusive worldwide license to commercialize NanoAbs for the treatment of COVID-19 The company plans to initiate a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023 BiondVax has exclusive options for worldwide licenses for NanoAbs to treat ot...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, was featured in a recent report published by Zacks Small-Cap Research. In the report, Z...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that its Head of Technical R&D, Dr. Dalit Weinstein Fischer , will...

BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference PR Newswire JERUSALEM , Nov. 3, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manu...

BiondVax provides plan to address Nasdaq compliance PR Newswire JERUSALEM , Nov. 2, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing i...